Cytokinetics Incorporated (NASDAQ: CYTK) |
|
Price: $42.1800
$0.62
1.492%
|
Day's High:
| $42.33
| Week Perf:
| -8.64 %
|
Day's Low: |
$ 40.53 |
30 Day Perf: |
-9.7 % |
Volume (M): |
1,786 |
52 Wk High: |
$ 81.36 |
Volume (M$): |
$ 75,329 |
52 Wk Avg: |
$56.77 |
Open: |
$40.65 |
52 Wk Low: |
$40.53 |
|
|
Market Capitalization (Millions $) |
4,964 |
Shares
Outstanding (Millions) |
118 |
Employees |
141 |
Revenues (TTM) (Millions $) |
3 |
Net Income (TTM) (Millions $) |
-576 |
Cash Flow (TTM) (Millions $) |
-53 |
Capital Exp. (TTM) (Millions $) |
3 |
Cytokinetics Incorporated
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to developing small molecule drugs that can be used to treat a variety of diseases. The company was founded in 1997 and is headquartered in South San Francisco, California. Since its inception, Cytokinetics has focused on developing drugs that can enhance the function of the muscles in the body, with an emphasis on skeletal and cardiac muscle.
Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.
Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.
Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.
Company Address: 350 Oyster Point Blvd South San Francisco 94080 CA
Company Phone Number: 624-3000 Stock Exchange / Ticker: NASDAQ CYTK
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Clinical Study
Published Tue, Jan 21 2025 1:07 PM UTC
Exploring Cytokinetics Groundbreaking Efforts in Heart Failure Therapy Cytokinetics, Incorporated, a biotechnology company focused on developing innovative treatments for cardiac and neuromuscular diseases, has made significant strides in the clinical landscape, particularly regarding heart failure with preserved ejection fraction (HFpEF). With the initiation of the AMBER-H...
|
Shares
Published Fri, Jan 3 2025 9:00 PM UTC
Cytokinetics Expands Workforce with Strategic Stock Grants: Assessing the Impact on the Company?s Share DynamicsCytokinetics, Incorporated, a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors, recently announced inducement grants to new employees under the Nasdaq Listing Rule 5635(c)(4). As the company s...
|
Management Announcement
Published Fri, Dec 20 2024 5:00 AM UTC
Impact Assessment of Cytokinetics? Strategic Developments and Talent AcquisitionCytokinetics Announces Drug Licensing Deal with SanofiOn December 20, 2024, Cytokinetics, a California-based biopharmaceutical company, announced an exclusive agreement with Sanofi for the development and commercialization of aficamten, a next-in-class cardiac myosin inhibitor. This drug aims to...
|
Shares
Published Tue, Dec 3 2024 9:00 PM UTC
In the hyper-competitive landscape of the biopharmaceutical industry, attracting and retaining top talent is paramount for innovation and progress. Cytokinetics, Incorporated, a California-based company renowned for its commitment to advancing therapies for cardiovascular diseases, has underscored this strategy in their recent announcement. On December 3, 2024, the company r...
|
Clinical Study
Published Sat, Nov 16 2024 2:00 PM UTC
Abstract: Recent analyses from the SEQUOIA-HCM study, presented by Cytokinetics at the American Heart Association Scientific Sessions 2024, highlight significant advances in the treatment of hypertrophic cardiomyopathy (HCM). The primary focus is on the investigational drug, aficamten, which has demonstrated promising results in improving post-exercise oxygen uptake recovery...
|
Per Share |
Current |
Earnings (TTM) |
-5.35 $ |
Revenues (TTM) |
0.03 $
|
Cash Flow (TTM) |
- |
Cash |
8.6 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-5.35 $
|
Revenues (TTM) |
0.03 $ |
Cash Flow (TTM) |
- |
Cash |
8.6 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
On February 13 2024 the Cytokinetics Incorporated provided following guidance
Cytokinetics, Incorporated, a biopharmaceutical company based in South San Francisco, announced today that it will release its fourth quarter financial results on February 27, 2024 at 4:00 PM Eastern Time. The co...
|
|
|